En Es
Categories

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection of HIV and syphilis at the point of care. It has products on the market in over 40 countries and seeks to develop new products to enable early and improved treatment of malaria, Ebola, febrile illness ...
Products Covid-19NewsSummary
Close

Covid-19 CHEMBIO DIAGNOSTIC SYSTEMS

Clinical Laboratory

COVID-19/Flu Rapid Test
Status COVID-19/Flu

The Status COVID-19/Flu is the only FDA EUA visual read rapid test for the simultaneous detection and differential diagnosis of SARS-CoV-2, Influenza Type A & Influenza Type B Antigen in nasopharyngeal swab specimens.
More details

SARS-CoV-2 Antigen Rapid Test
DPP SARS-CoV-2 Antigen

The DPP SARS-CoV-2 Antigen is a CE Marked rapid test for the detection of nucleocapsid protein antigen to SARS-CoV-2 in nasal swab specimens. The results can either be read visually, with our DPP Micro Reader or our DPP Micro Reader II.
More details

Digital Reader
DPP Micro Reader

The DPP Micro Reader is a handheld device that enables testing for SARS-CoV-2 and other DPP tests. The maintenance free reader streamlines the point-of-care testing experience with precise and accurate results, minimizing human errors due to visual interpretation.
More details

Digital Reader
DPP Micro Reader II

The DPP Micro Reader II is a handheld device that enables testing for SARS-CoV-2 and streamlines the point-of-care testing experience with precise and accurate results. The maintenance free reader delivers automated results in 15-20 seconds and minimizes human errors due to visual interpretation.
More details

COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System

The DPP COVID-19 IgM/IgG System is an ANVISA Approved rapid test for the detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in capillary “fingerstick” whole blood, venous whole blood, serum and plasma samples. A simple to use, handheld, portable DPP Micro Reader provides simultaneous and separate detection of IgM and IgG antibodies to SARS-CoV-2 in 15 minutes using a small sample size of only 10 μL.
More details
Close

News of CHEMBIO DIAGNOSTIC SYSTEMS

Chembio Diagnostics Announces Two New Senior-Level Appointments

25 Oct 2016
Chembio Diagnostics Announces Two New Senior-Level Appointments
Chembio Diagnostics, Inc., which develops, manufactures, licenses and markets rapid point-of-care (POC) diagnostic tests for infectious diseases, has made two new senior-level appointments.
Read More
Close

About CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection of HIV and syphilis at the point of care. It has products on the market in over 40 countries and seeks to develop new products to enable early and improved treatment of malaria, Ebola, febrile illness, dengue fever and influenza.
FaceBook Twitter Google+ Linked in
DPP Zika IgM/IgG System

DPP Zika IgM/IgG System

Model: DPP Zika IgM/IgG System
Request Information

Description:

The DPP Zika IgM/IgG System comprises single-use point-of-care (POC) assays for use with a reader for the discrete, semi-quantitative detection of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to Zika Virus. It uses ready-to-use reagents (no special preparation of reagents required) and a simple procedure to deliver rapid results in 15 minutes.


Send A Message To This Supplier

* Required Information
* Email
To
CHEMBIO DIAGNOSTIC SYSTEMS (DPP Zika IgM/IgG System)
* Message

Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions